The White House has scheduled a total of four meetings this week with cannabis industry and research stakeholders to discuss CBD product enforcement policy.
The Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) announced earlier this month plans to revise the yet-to-be-published “Cannabidiol (CBD) Product Compliance and Enforcement Policy.” It was introduced by the Food and Drug Administration (FDA).
Interested parties can request meetings to discuss the issue — and four meetings have now been scheduled for April 1-2.
David Heldreth, CEO of Panacea Plant Sciences, was the first to secure a meeting with OIRA, and told Marihuana Moment last week that he plans to use the opportunity. encourage the FDA to develop more holistic guidance on CBD that goes beyond cannabinoid isolates.
Since then, the White House has done it accepted requests for meetings to discuss the yet-to-be-published CBD rule with Trent Woloveck of multi-state cannabis operator Jushi Holdings on Wednesday, as well as Mackie Barch of Story Cannabis and Iowa hemp farmer Earl Ramey on Thursday.
All of this comes less than a month before changes to federal hemp laws are set to significantly shake up the industry, with a ban on most consumable cannabinoids containing THC taking effect in November. As part of the original law, the FDA was responsible for publishing a list of known cannabinoids, however He missed a deadline set by the congress to fulfill this obligation and it is not clear when that list will finally be issued.
Some have speculated that the enforcement policy guidance being considered by OIRA is related to the executive order President Donald Trump signed in December to move marijuana from Schedule I to III of the Controlled Substances Act (CSA), which also included provisions for the Centers for Medicare and Medicaid Services (CMS) to create a pathway for CBD health care coverage.
To that end, CMS recently shared new details about that plan, which will allow patients enrolled in insurance programs up to the maximum. $500 of hemp-derived products are covered annually starting Wednesday.
The CBD-focused plan will also allow a certain amount of THC in the products, but the agency said the planned rules could change if federal hemp policies change, as is currently expected under the law that will take effect in November.
Participants would have to ensure that the CBD comes from a “law-compliant source and high-quality farm,” prepared as an oral solution, and tested for cannabinoid content, so that available products contain no more than 0.3 percent delta-9 THC by dry weight and a total of 3 milligrams of THC per serving.
CMS said that centers participating in one of three models that receive substance access beneficiary engagement incentives (BEI) “will be able to consult with eligible beneficiaries about the use of eligible hemp products to improve symptom control.”
The new details about the rules for the CBD pilot program come weeks after a co-founder of the Charlotte’s Web hemp company, which has partnered with CMS, told the agency. ended federal health insurance plans for cannabidiol.
—
It’s Marijuana Moment tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.
Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—
While CMS issued a previous final rule this past April specifically stipulating that marijuana, as well as CBD derived from federal law hemp, are ineligible For coverage of the Medicare Advantage program and other services, the agency is revising that policy.
CMS already announced some changes as part of a rulemaking process filed late last year, It affects “marketing and communications, drug coverage, enrollment processes, special needs plans and other programming areas.” for the insurance programs it oversees. One of these changes concerned the coverage of cannabidiol.
Meanwhile, regarding the marijuana components of Trump’s December executive order, Attorney General Pam Bondi ordered a quick end to the cannabis redistricting proposal, which would not federally legalize it, but would remove some barriers to research and allow state-licensed marijuana businesses to take federal tax deductions known as the Internal Revenue Service (2S)80E Service. This proposal to reconsider, however, is still pending.